Clinical stage drug development company Syntara Limited (ASX: SNT) is pleased to announce that its abstract1 has been has been selected for an oral presentation at the American Society of Haematology meeting (ASH) where interim results from its Phase 2 trial evaluating SNT-5055, in combination with ruxolitinib to treat the bone marrow cancer myelofibrosis, will be presented.
ASH takes place from 7-10 December 2024 in San Diego and is the largest haematology scientific conference held globally, attended by over 30,000 scientists, clinicians, companies and investors from more than 100 countries.
Abstracts for this year’s ASH Meeting and Exposition were made available earlier today, with a record-breaking number of abstracts submitted and more than 7,950 accepted.
Syntara’s abstract has been identified as one of a select group to be given an oral presentation, scheduled for 5:30pm PT on 9 December 2024.
